Expanded Access to Epcoritamab
- Sponsor
- AbbVie
- Study ID
- NCT05692050
- Status
- No Longer Available
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Epcoritamab — DRUGSubcutaneous Injection
Study Details
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to epcoritamab prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Key Dates
- Status verified
- Feb 2023
Related Studies
- Bone Marrow Grafting for Leukemia and LymphomaEnrolling By Invitation · Stanford University · Stanford, California
- Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative DisordersRecruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerRecruiting · Barbara Ann Karmanos Cancer Institute · Detroit, Michigan
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruiting · UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina